Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexelvucitabine
- Development stage
- Discontinued
- Lead developer
- Incyte
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Dexelvucitabine is an investigational nucleoside reverse transcriptase inhibitor (NRTI) that was developed for the treatment of HIV infection. It is a cytidine analogue designed to inhibit HIV-1 reverse transcriptase by incorporating into viral DNA and causing chain termination during viral replication. Dexelvucitabine showed antiviral activity in preclinical and early clinical studies but its development was discontinued due to concerns about toxicity, particularly lactic acidosis and hepatotoxicity. The drug was never approved for marketing.
- Brand names
- Reverset
- Other names
- DFCReverset
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on dexelvucitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexelvucitabine.